Clinical Trials - January 11, 2016
Active Biotech’s partner amend trial design
Active Biotech’s partner Teva Pharmaceutical Industries will amend the trial design in a Phase 2 study of laquinimod in Huntington’s disease. The amendment consists of dropping the highest of three doses (1.5 mg/day) in the trial while keeping two remaining active doses (0.5 and 1 mg/day) unchanged. This is a precautionary measure in the interest […]
Biotech Business - May 3, 2015
Active to Lay Off 47 Workers
A month after Swedish company Active Biotech AB reported that its Phase III trial of 10TASQ10 in castration-resistant prostate cancer reached its primary endpoint but did not increase peoples’ overall survival, the company announced plans to lay off 47 people. Active Biotech and French company Ipsen collaborated on the study of 10TASQ10 (tasquinimod). While the drug reduced the risk of radiographic cancer […]
Clinical Trials - April 28, 2015
Trial Starts for PPMS Drug
Teva Pharmaceutical Industries Ltd. and Active Biotech enrolled the first patient in their study A RandomizedPlacebo-controlled Trial Evaluating Laquinimod in primary progressive multiple sclerosis (PPMS), Gauging Gradations In MRI and Clinical Outcomes (ARPEGGIO), a Phase II study to evaluate laquinimod. This is an investigational, oral, immune modulator, for PPMS, which currently has no approved treatments. PPMS affects approximately 15 percent of all MS patients […]
Clinical Trials - April 20, 2015
Active Biotech Shares Plunge
Shares of Ipsen and partner Active Biotech plunged last week after Ipsen’s experimental prostate cancer drug Tasquinimod failed during a Phase III trial. Active’s shares dropped 60 percent and Ipsen’s went down by 10 percent. “The data at hand is unambiguous and cannot motivate further development of tasquinimod in this patient population,” said Tomas Leanderson, […]
Clinical Trials - August 15, 2014
Active Biotech’s partner Teva starts laquinimod clinical trial
Active Biotech has announced that its partner Teva Pharmaceutical Industries Ltd. will initiate a phase II clinical trial to evaluate the efficacy and safety of oral laquinimod for the treatment of Huntington’s disease. Teva started a global research collaboration in the summer of 2013 to develop laquinimod as a treatment for Huntington’s disease. Earlier this year, […]
Drug Development Pharma - May 23, 2014
CHMP says no to Laquinimod
Teva Pharmaceutical and Active Biotech has announced that the Committee for Medicinal Products for Human Use’s confirmed its earlier opinion to recommend against approval for the treatment of relapsing-remitting multiple sclerosis in the European Union at this time. According to a statement from Active Biotech, both companies remain committed to the NERVENTRA (laquinimod) clinical development program for […]
